Table 1 Initial therapeutic regimens

From: Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group

Regimen

No. of patients

VCD

19

PAD

8

VDT PACE

4

VDT

2

MPV

2

VD

3

MPT

2

VAD

6

MP

4

ASCT

16

Double ASCT

2

Allo-SCT

1

  1. VCD cyclophosphamide, bortezomib, dexamethasone, VD bortezomib, dexamethasone, PAD bortezomib, adriamycin, dexamethasone, VDTPACE bortezomib, dexamethasone, thalidomide, cisplatinum, adriamycin, cyclophosphamide, etoposide, VDT bortezomib, dexamethasone, thalidomide, MPV melphalan, prednisone, bortezomib, VD bortezomib, dexamethasone, MPT melphalan, prednisone, thalidomide, VAD vincristine, adriamycin, dexamethasone, MP melphalan, prednisone, ASCT autologous stem-cell transplantation, Allo-SCT allogeneic stem cell transplantation
Back to article page